K-numberK243892
Device nameAffera Integrated Mapping System
ApplicantMedtronic, Inc.
Product codeDQK
Device classClass II
Decision dateJan 17, 2025
DecisionSubstantially Equivalent
Regulation870.1425
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Affera Integrated Mapping System is a computerized diagnostic system for catheter-based cardiac electrophysiology procedures. It provides real-time visualization of compatible catheters, displays electroanatomical maps in multiple formats, records body surface ECG and intracardiac electrogram signals, and can deliver pacing stimuli. The system uses magnetic localization technology with optional hybrid electromagnetic-impedance tracking to visualize both sensor-equipped catheters and third-party devices.

Technological characteristics

The subject device shares the same magnetic-based tracking of embedded sensors and hybrid electromagnetic-impedance tracking capabilities as the predicate. Both use a catheter interface unit, magnetic field generator, and software workstation to create 3D geometric shell, voltage, activation, and propagation maps. The key difference is that the subject device adds a software feature allowing users to select ECG electrodes as the impedance reference point, whereas the predicate only measured impedance reference from a stable intracardiac catheter.

Test standards cited

Not stated in this summary. The document references that testing was completed in accordance with 'appropriate standards' but does not cite specific ISO, IEC, ASTM, or other consensus standards by number.

Substantial equivalence argument

The subject device is substantially equivalent because it shares identical intended use and indications for use with the predicate, employs the same fundamental magnetic-based and hybrid electromagnetic-impedance tracking technologies, and uses identical key system components and map types. The addition of ECG-based impedance reference selection does not raise new safety or effectiveness questions—it merely provides an alternative method for establishing the impedance measurement zero point while maintaining the same overall diagnostic functionality. All performance testing met acceptance criteria, and no new safety or effectiveness concerns emerged from the testing.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →